001     142207
005     20240229105147.0
024 7 _ |2 doi
|a 10.1093/neuonc/noy118
024 7 _ |2 pmid
|a pmid:30053291
024 7 _ |2 pmc
|a pmc:PMC6231197
024 7 _ |2 ISSN
|a 1522-8517
024 7 _ |2 ISSN
|a 1523-5866
024 7 _ |a altmetric:45451078
|2 altmetric
037 _ _ |a DKFZ-2019-00021
041 _ _ |a eng
082 _ _ |a 610
100 1 _ |0 P:(DE-He78)046fd145f1008f83f6236580727bbc0f
|a Witt, Hendrik
|b 0
|e First author
245 _ _ |a DNA methylation-based classification of ependymomas in adulthood: implications for diagnosis and treatment.
260 _ _ |a Oxford
|b Oxford Univ. Press
|c 2018
336 7 _ |2 DRIVER
|a article
336 7 _ |2 DataCite
|a Output Types/Journal article
336 7 _ |0 PUB:(DE-HGF)16
|2 PUB:(DE-HGF)
|a Journal Article
|b journal
|m journal
|s 1550670671_25911
336 7 _ |2 BibTeX
|a ARTICLE
336 7 _ |2 ORCID
|a JOURNAL_ARTICLE
336 7 _ |0 0
|2 EndNote
|a Journal Article
520 _ _ |a Ependymal tumors are glial tumors that commonly manifest in children and young adults. Their classification has remained entirely morphological until recently, and surgery and radiotherapy are the main treatment options, especially in adults. Here we sought to correlate DNA methylation profiles with clinical and pathological characteristics in the prospective cohort of the German Glioma Network.Tumors from 122 adult patients with myxopapillary ependymoma, ependymoma, anaplastic ependymoma, subependymoma, or RELA fusion-positive ependymoma classified according to the World Health Organization (WHO) 2016 were subjected to DNA methylation profiling using the Illumina HumanMethylation450 BeadChip platform. Molecular data were correlated with histologic features and clinical characteristics.At a median follow-up of 86.7 months, only 22 patients experienced progression (18.0%) and 13 patients (10.7%) died. Each tumor could be assigned to one of the previously defined molecular ependymoma subgroups. All histologic subependymomas corresponded to subependymoma (SE) DNA methylation subgroups, but the reverse was not true: 19 histologic ependymomas (WHO grade II) were allocated to molecular SE groups. Similarly, all histological myxopapillary ependymomas were assigned to the molecularly defined spinal myxopapillary ependymoma (SP-MPE) class, but this molecular subgroup additionally included 15 WHO grade II ependymomas by histology. Overall, WHO grade II ependymomas distributed into 7 molecular subgroups.Most adult patients with ependymoma show a favorable prognosis. Molecular classification may provide diagnostic and prognostic information beyond histology and facilitate patient stratification in future clinical trials. The prognostic significance of a subependymoma or myxopapillary ependymoma DNA methylation phenotype without corresponding histology requires further study.1. Ependymoma diagnosed in adult patients most often shows a good prognosis. 2. Molecular classification can support diagnostic and prognostic information beyond histology.
536 _ _ |0 G:(DE-HGF)POF3-312
|a 312 - Functional and structural genomics (POF3-312)
|c POF3-312
|f POF III
|x 0
588 _ _ |a Dataset connected to CrossRef, PubMed,
700 1 _ |a Gramatzki, Dorothee
|b 1
700 1 _ |a Hentschel, Bettina
|b 2
700 1 _ |0 P:(DE-He78)a7c1bbac024fa232d9c6b78443328d9d
|a Pajtler, Kristian
|b 3
700 1 _ |0 P:(DE-HGF)0
|a Felsberg, Jörg
|b 4
700 1 _ |a Schackert, Gabriele
|b 5
700 1 _ |a Löffler, Markus
|b 6
700 1 _ |0 P:(DE-He78)51bf9ae9cb5771b30c483e5597ef606c
|a Capper, David
|b 7
|u dkfz
700 1 _ |0 P:(DE-He78)a1f4b408b9155beb2a8f7cba4d04fe88
|a Sahm, Felix
|b 8
700 1 _ |0 P:(DE-He78)45440b44791309bd4b7dbb4f73333f9b
|a Sill, Martin
|b 9
700 1 _ |0 P:(DE-He78)a8a10626a848d31e70cfd96a133cc144
|a von Deimling, Andreas
|b 10
700 1 _ |0 P:(DE-He78)4c28e2aade5f44d8eca9dd8e97638ec8
|a Kool, Marcel
|b 11
700 1 _ |a Herrlinger, Ulrich
|b 12
700 1 _ |a Westphal, Manfred
|b 13
700 1 _ |a Pietsch, Torsten
|b 14
700 1 _ |0 P:(DE-HGF)0
|a Reifenberger, Guido
|b 15
700 1 _ |0 P:(DE-He78)f746aa965c4e1af518b016de3aaff5d9
|a Pfister, Stefan
|b 16
700 1 _ |a Tonn, Jörg C
|b 17
700 1 _ |a Weller, Michael
|b 18
700 1 _ |a Network, German Glioma
|b 19
|e Collaboration Author
773 _ _ |0 PERI:(DE-600)2094060-9
|a 10.1093/neuonc/noy118
|g Vol. 20, no. 12, p. 1616 - 1624
|n 12
|p 1616 - 1624
|t Neuro-Oncology
|v 20
|x 1523-5866
|y 2018
909 C O |o oai:inrepo02.dkfz.de:142207
|p VDB
910 1 _ |0 I:(DE-588b)2036810-0
|6 P:(DE-He78)046fd145f1008f83f6236580727bbc0f
|a Deutsches Krebsforschungszentrum
|b 0
|k DKFZ
910 1 _ |0 I:(DE-588b)2036810-0
|6 P:(DE-He78)a7c1bbac024fa232d9c6b78443328d9d
|a Deutsches Krebsforschungszentrum
|b 3
|k DKFZ
910 1 _ |0 I:(DE-588b)2036810-0
|6 P:(DE-HGF)0
|a Deutsches Krebsforschungszentrum
|b 4
|k DKFZ
910 1 _ |0 I:(DE-588b)2036810-0
|6 P:(DE-He78)51bf9ae9cb5771b30c483e5597ef606c
|a Deutsches Krebsforschungszentrum
|b 7
|k DKFZ
910 1 _ |0 I:(DE-588b)2036810-0
|6 P:(DE-He78)a1f4b408b9155beb2a8f7cba4d04fe88
|a Deutsches Krebsforschungszentrum
|b 8
|k DKFZ
910 1 _ |0 I:(DE-588b)2036810-0
|6 P:(DE-He78)45440b44791309bd4b7dbb4f73333f9b
|a Deutsches Krebsforschungszentrum
|b 9
|k DKFZ
910 1 _ |0 I:(DE-588b)2036810-0
|6 P:(DE-He78)a8a10626a848d31e70cfd96a133cc144
|a Deutsches Krebsforschungszentrum
|b 10
|k DKFZ
910 1 _ |0 I:(DE-588b)2036810-0
|6 P:(DE-He78)4c28e2aade5f44d8eca9dd8e97638ec8
|a Deutsches Krebsforschungszentrum
|b 11
|k DKFZ
910 1 _ |0 I:(DE-588b)2036810-0
|6 P:(DE-HGF)0
|a Deutsches Krebsforschungszentrum
|b 15
|k DKFZ
910 1 _ |0 I:(DE-588b)2036810-0
|6 P:(DE-He78)f746aa965c4e1af518b016de3aaff5d9
|a Deutsches Krebsforschungszentrum
|b 16
|k DKFZ
913 1 _ |0 G:(DE-HGF)POF3-312
|1 G:(DE-HGF)POF3-310
|2 G:(DE-HGF)POF3-300
|a DE-HGF
|l Krebsforschung
|v Functional and structural genomics
|x 0
|4 G:(DE-HGF)POF
|3 G:(DE-HGF)POF3
|b Gesundheit
914 1 _ |y 2018
915 _ _ |0 StatID:(DE-HGF)0420
|2 StatID
|a Nationallizenz
915 _ _ |0 StatID:(DE-HGF)0100
|2 StatID
|a JCR
|b NEURO-ONCOLOGY : 2017
915 _ _ |0 StatID:(DE-HGF)0200
|2 StatID
|a DBCoverage
|b SCOPUS
915 _ _ |0 StatID:(DE-HGF)0300
|2 StatID
|a DBCoverage
|b Medline
915 _ _ |0 StatID:(DE-HGF)0310
|2 StatID
|a DBCoverage
|b NCBI Molecular Biology Database
915 _ _ |0 StatID:(DE-HGF)0320
|2 StatID
|a DBCoverage
|b PubMed Central
915 _ _ |0 StatID:(DE-HGF)0199
|2 StatID
|a DBCoverage
|b Clarivate Analytics Master Journal List
915 _ _ |0 StatID:(DE-HGF)0111
|2 StatID
|a WoS
|b Science Citation Index Expanded
915 _ _ |0 StatID:(DE-HGF)0150
|2 StatID
|a DBCoverage
|b Web of Science Core Collection
915 _ _ |0 StatID:(DE-HGF)1110
|2 StatID
|a DBCoverage
|b Current Contents - Clinical Medicine
915 _ _ |0 StatID:(DE-HGF)9905
|2 StatID
|a IF >= 5
|b NEURO-ONCOLOGY : 2017
920 1 _ |0 I:(DE-He78)B062-20160331
|k B062
|l Pädiatrische Neuroonkologie
|x 0
920 1 _ |0 I:(DE-He78)G380-20160331
|k G380
|l KKE Neuropathologie
|x 1
920 1 _ |0 I:(DE-He78)L101-20160331
|k L101
|l DKTK Heidelberg
|x 2
920 1 _ |0 I:(DE-He78)L401-20160331
|k L401
|l DKTK Essen
|x 3
920 1 _ |0 I:(DE-He78)L201-20160331
|k L201
|l DKTK Berlin
|x 4
920 1 _ |0 I:(DE-He78)L301-20160331
|k L301
|l DKTK Dresden
|x 5
920 1 _ |0 I:(DE-He78)L701-20160331
|k L701
|l DKTK München
|x 6
980 _ _ |a journal
980 _ _ |a VDB
980 _ _ |a I:(DE-He78)B062-20160331
980 _ _ |a I:(DE-He78)G380-20160331
980 _ _ |a I:(DE-He78)L101-20160331
980 _ _ |a I:(DE-He78)L401-20160331
980 _ _ |a I:(DE-He78)L201-20160331
980 _ _ |a I:(DE-He78)L301-20160331
980 _ _ |a I:(DE-He78)L701-20160331
980 _ _ |a UNRESTRICTED


LibraryCollectionCLSMajorCLSMinorLanguageAuthor
Marc 21